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The down-regulation fpH]PDBu binding to a neural cell line, NG115-401L, has been examined inresponse 
to two biologically active phorbol diesters, PDBu and PMA. Chronic treatment with PDBu or PMA causes 
a concentration- and time-dependent loss of specific pH]PDBu binding. The action of PMA is biphasic with 
respect to both concentration a d time dependence. 
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1. INTRODUCTION 
It is now widely recognised that the high-affinity 
binding site of tumour-promoting and pro- 
inflammatory phorbol diesters may correspond to 
the intracellular enzyme PKC [1]. Activation of 
this kinase produces a variety of biological effects, 
including actions in neurones [2-4]. 
In several cell types, long-term exposure to phor- 
bol diesters has been shown to reduce both amount 
and activity of PKC [5-8]. This down-regulation 
attracts interest for several reasons: (i) it may be 
elicited by hormone receptor activation in some 
circumstances [5]; (ii) its mechanism is unknown; 
(iii) it can be used to produce 'PKC-deficient' ceils 
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in the absence of specific, well-characterised PKC 
antagonists [3]. Recent reports of tissue-specific 
expression of a number of different protein kinases 
C [9] highlight he need to characterise such down- 
regulation in different differentiated cell popula- 
tions. Here we report that homologous down- 
regulation of the high-affinity [3H]PDBu-binding 
site in the neuronal-like cell line NGll5-401L is 
structure-, concentration- and time-dependent. 
2. MATERIALS AND METHODS 
Cells were cultured at 37°C in 8°70 CO2 and 
maintained in DMEM supplemented with 5070 FCS 
and antibiotics. For binding measurements, cells 
were grown on 24-well plates (5 × 105 cells/well) 
and cultured for 48 h prior to each experiment. All 
experiments were conducted at room temperature. 
The DMEM was aspirated and the ceils incubated 
for I0 min prior to addition of the radioactive 
ligand. When the cells had been pre-exposed to 
phorbol esters, the medium was aspirated, the cells 
washed 3 times with 0.5 ml HGB at 37°C and the 
third wash left in the well for a further 20 min 
while the plate was kept at 37°C. In control ex- 
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periments this washing procedure was shown to 
remove 99.5070 of previously added [3H]PDBu. 
All binding assays were performed with 0.5 ml 
per well of HGB containing 10 nM [3H]PDBu 
(12.5 Ci/mol, New England Nuclear) plus its vehi- 
cle ethanol (max. 2.5070) with 60 min allowed for 
equilibration. Non-specific binding was defined in 
the presence of 20/~M unlabelled PDBu (Sigma). 
The incubations were ended by "aspiration and 
rapid washing (3 × 0.5 ml ice-cold HGB). Wells 
were extracted and washed with 2 × 0.75 ml of a 
1070 Triton X-100 solution containing 1 mg/ml 
BSA. Pooled extracts were counted in 10 ml 
Hydrofluor (National Diagnostics); efficiency ap- 
prox. 41070. 
For chronic treatment, phorbols were added 
from a solution in DMEM plus dimethyl sulphox- 
ide vehicle (max. 1.6070). The concentration and 
duration of treatment are given in the figure 
legends. 
3. RESULTS 
Fig. 1 shows that 24 h treatment with PDBu or 
PMA causes a dose-dependent reduction in 
specific [3H]PDBu binding. The effect of PMA is 
biphasic; a reduction to about 50°70 control 
binding occurring from 10 to 100 nM, and above 
200 nM a complete abolition of binding. 
The dose-response relationship to PDBu shows a 
maximal reduction of about 60070 in control 
binding. The effect of PDBu is also less potent 
than that of PMA at any given concentration 
tested. The non-esterified /~-phorbol (Sigma), 
which lacks biological activity [10] and was used 
here as a control, produced no effect. 
Fig.2 shows the time course of the down- 
regulation to PMA, comparing the results for the 
two concentrations 20 and 200 nM. Fig.3 shows a 
graphical transformation of the data for 200 nM 
PMA, It is apparent that the response to the higher 
concentration consists of two exponential pro- 
cesses; the rapid phase having a h/2 of 1.5 h and 
the slow phase a t~/2 of 13 h. A slow phase with 
similar kinetics is also present in the response to 
20 nM PMA treatment. The lower concentration 
has a complex effect at short time points, however, 
such that at 90 min there is a significant increase in 
specific binding above control (P < 0.025). Thus, 
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Fig. 1. Concentration dependence of down-regulation f 
specific [3H]PDBu binding by PDBu or PMA treatment. 
100% specific binding, defined in the absence of any 
treatment, represented approx. 87 fmol ligand bound 
per well. Points shown are the means +__ SD of three 
independent experiments conducted in triplicate 
samples• 
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Fig.2. Time course of down-regulation of specific 
[3H]PDBu binding elicited by PMA treatment. 100% 
specific binding defined in the absence of any treatment. 
Points shown are means of three independent 
experiments conducted in triplicate samples (20, 40, 60, 
90 rain and 4, 24 h) or two independent experiments of
quadruplicate samples (2, 8, 12, 18h). Standard 
deviations of the individual points were 1-15010. 
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Fig.3. Graphical transformation of data for 200 nM 
PMA treatments shown in fig.2. 
after 4 h at the lower concentration the binding is 
unchanged from control at 99 _+ 1%, whereas after 
2 h of 200 nM PMA treatment there has been a 
striking reduction in the level of binding to only 
26_+ 1%. 
4. DISCUSSION 
These results show a clear distinction between 
the two most commonly used active phorbol 
diesters, PDBu and PMA, in eliciting down- 
regulation. PDBu was developed by Driedberg and 
Blumberg [11] as a ligand with the optimal ratio of 
specific binding to non-specific uptake. In con- 
trast, while PMA is known to be the most potent 
phorbol ester in several biological responses, its 
high lipophilicity means that it readily partitions 
into membranes to give a large, non-saturable 
binding. The potency and extent of the down- 
regulation in response to these two ligands are 
quite different• The failure of PBDu treatment to 
produce complete down-regulation f [3H]PDBu 
binding has also been reported in Swiss 3T3 
fibroblasts [8] and AtT-20/D16V clonal pituitary 
cells [6]. The lack of effect of ~'-phorbol confirms 
that only biologically active phorbols produce 
down-regulation. Two different concentrations of 
PMA provoke two different ime courses for loss 
of specific phorbol-binding sites. At the higher 
concentration (200 riM), the time course can be fit- 
ted by two exponential processes (fig.3), whereas 
at the lower concentration (20 nM), there is an in- 
itial rapid loss, followed by a transient increase in 
binding. In each case the final decay of specific 
binding appears kinetically equivalent. This sug- 
gests that the early loss of binding with sustained 
application of phorbol diesters may be particularly 
sensitive to concentration. It is intriguing to con- 
sider whether the lower concentration of PMA 
may more closely mimic the possible regulation of 
the phorbol binding site in response to the activa- 
tion of cell surface receptors [5]. 
The loss of functional PKC following chronic 
phorbol exposure has been suggested to have two 
sequential steps; an initial desensitisation with no 
change in binding properties, followed by a 
decrease in binding sites [6]. In several cell types, 
the second stage may be due to an increased rate of 
PKC degradation [12]. The slower phase of down- 
modulation, which is present in response to both 
concentrations of PMA tested, is more likely to be 
consistent with actual PKC loss. It is an interesting 
possibility for future investigation that the more 
rapid events in the alteration of binding could 
reflect changes in the affinity of the site. 
An added complexity to be considered is that re- 
cent reports have identified several closely related 
but distinct forms of protein kinases C [9]. It is 
likely that any individual clonal cell line may ex- 
press different protein kinases C with their cognate 
phorbol diester eceptors, thus some heterogeneity 
in binding characteristics and down-regulation 
should not be unexpected. 
In conclusion we would suggest that to produce 
fully down-modulated, and presumably maximally 
PKC-deficient, NGll5-401L cells, treatment with 
PMA (>200nM, >12h) should be used in 
preference to treatment with PDBu. 
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